KR102474843B1 - Anti-aging composition and skin external composition compring the same - Google Patents

Abstract

The present invention provides an anti-aging composition comprising a first substance comprising a phytoplacenta extract, a second substance comprising a growth hormone, and a third substance comprising core-shell particles. The core comprises an effective substance. The shell is composed of an inner shell surrounding the core and an outer shell surrounding the inner shell and located at the outermost layer of the shell. The inner shell comprises one or more selected from a group consisting of zein, hordein, secalin, kafirin, gliadin, oryzin, and avenin, and the outer shell comprises pullulan and pectin.

Description

Anti-aging composition and composition for external application for skin containing the same {ANTI-AGING COMPOSITION AND SKIN EXTERNAL COMPOSITION COMPRING THE SAME}

The present disclosure relates to an anti-aging composition and an external composition for skin containing the same.

Lamin protein is a protein constituting the fibrillar network in the cell nucleus. Lamin is divided into A type and B type according to the protein structure and gene expression pattern. Lamin A is a protein that forms the lamina just inside the nuclear membrane of cells. Mutations in the lamin A gene cause diseases called laminopathy. Representative examples are Hutchison Gilford progeria syndrome (HGPS) and MAD (Atypical Werner's syndrome and mandibuloacral dysplasia) are known. Most of the cases of progeria occur when cytosine in the 1824 gene is replaced with thymine, and at this time, when the lamin gene is expressed as a protein, truncated lamin A is produced.

Representative features of premature aging include sclerodermatous skin, hair loss, abnormal bone formation, delayed tooth formation, stunted growth, loss of subcutaneous fat, and the like. In the case of patients with progeria, abnormal symptoms have been reported in cell nuclear structure and function, and a typical example is a deformed cell nuclear structure (nuclear aberration).

Also, in a recent study, alterations in cell nuclear structure have been found in normal elderly people without progeria. Nuclear structural abnormalities in the elderly aged 81-96 years are very similar to those of progeria patients.

Therefore, it was necessary to search for a substance that regulates the expression of the modified lamin A protein and the modification of the cell nuclear structure for the study of aging inhibition, and thus the present inventors specifically prevented cell damage by ultraviolet rays or anti-aging (aging suppression), and research on effective substances that can play a role and how to effectively deliver them to the body began.

On the other hand, in the cosmetic industry or pharmaceutical industry, when formulations for external use on the skin contain active substances that are difficult to penetrate the stratum corneum, synthetic surfactants have been used to promote skin absorption of the active substances. Alternatively, a method of increasing the skin permeability of an effective substance by using polymer nanoparticles or liposome nanoparticles using synthetic polymers such as polyethylene glycol as a carrier has been widely used. For example, polar solvents with low molecular weight such as ethanol, propylene glycol, dimethyl sulfoxide, and amphiphilic compounds are used together, or fatty acids with polar head groups and hydrophobic chains of amphiphilic compounds, alcohols, and 1-dodecylase Pan-2-one (Azone), 2-nonyl-1,3-dioxalane (SEPA 009), dodecyl-2-dimethylaminopropanoate (DDAIP) compounds and the like were used. However, since the above amphiphilic enhancers are synthetic compounds or organic solvents are used during manufacture, there are safety issues such as toxicity and allergen issues in the human body, and the cosmetics and pharmaceutical industries are trying to avoid their use. Therefore, it is necessary to develop a method that is friendly to the human body and the environment and can effectively enhance the percutaneous absorption of active substances.

Under the above background, the present inventors have been researching and developing for many years a composition capable of obtaining anti-aging efficacy by reducing damage to lamin A caused by UV stimulation, and after numerous failures and trials and errors, the present inventors have finally found the present invention. came to complete the invention.

One embodiment is to provide an anti-aging composition that reduces damage to lamin A caused by UV stimulation.

Another embodiment is to provide a composition for external application for skin comprising the anti-aging composition.

According to one embodiment, a first material containing a phytoplacenta extract, a second material containing growth hormone, and a third material containing core-shell particles are included, wherein the core contains an active material, and the shell surrounds the core. It consists of an inner shell and an outer shell located on the outermost layer of the shell while surrounding the inner shell, and the inner shell is composed of zein, hordein, secalin, kafirin, It provides an anti-aging composition comprising at least one selected from the group consisting of gliadin, oryzin, and avenin, and wherein the outer shell includes pullulan and pectin.

The pullulan included in the outer shell surrounds the core and the inner shell, and the pectin included in the outer shell is located in the outermost layer of the shell, forming an interconnection network between particles composed of the core and the inner shell to form a network structure can be achieved.

The network structure may be a delivery system for promoting transdermal absorption of an active substance.

The active substance may include saponin.

The core may further include maltodextrin.

The maltodextrin may be included in a higher content than the saponin.

The pullulan may be included in an amount greater than that of the pectin.

The third material may further include hexanediol, ethylhexylglycerin, citric acid, or a combination thereof.

The growth hormone may include a compound represented by Chemical Formula 1 below.

[Formula 1]

In Formula 1,

X is *-NH-*, *-O-*, *-S-* or *-CR ² R ³ (R ² and R ³ are each independently a hydrogen atom or a substituted or unsubstituted C1 to C10 alkyl group) ego,

R ¹ is a substituted or unsubstituted C1 to C20 alkyl group or carboxyl group.

The second material may further include a C1 to C20 alkylene glycol, a disaccharide, or a combination thereof.

The C1 to C20 alkylene glycol may be included in a greater amount than the disaccharide.

Indoleacetic acid in the second material may be included in the smallest content.

The phytoplacenta extract may include a rye phytoplacenta extract.

The first material may further include glycerin.

The rye phytoplacenta extract may be included in a lower content than the glycerin.

An average particle size of the core-shell particles may be greater than 100 nm and less than or equal to 600 nm.

The second material may be included in an amount equal to or less than that of each of the first material and the second material.

The second material may be included in a concentration of 2.1% or more relative to the total concentration of the anti-aging composition.

The second material may be included in a concentration of 25 ppm or more.

According to another embodiment, a composition for external application for skin containing the anti-aging composition is provided.

The composition for external application for skin may be a cosmetic composition, a pharmaceutical composition, a composition for preventing cell nuclear membrane damage induced by ultraviolet irradiation, or a composition for inhibiting the expression of a modified lamin A protein.

Since the anti-aging composition according to one embodiment can minimize damage to the lamin A structure caused by UV stimulation, a direct anti-aging effect can be realized through a composition for external application for skin containing the anti-aging composition.

1 is a schematic diagram showing core-shell particles included in a third material, which is one component constituting an anti-aging composition according to an embodiment, and core-shell particles containing an active substance in which the active substance is collected in the core.
Figure 2 is a graph measuring the number of cells having a modified lamin A structure in the compositions according to Example 1, Comparative Example 1 and Control.
Figure 3 is a confocal micrograph of the composition according to the control.
4 is a confocal micrograph of a composition according to Comparative Example 1.
5 is a confocal micrograph of a composition according to Example 1.
Figure 6 is a chemical structure showing 15 structures among the structures of camellia seed-derived saponin.

Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily implement the present invention. However, the present invention may be embodied in many different forms and is not limited to the embodiments set forth herein.

Unless otherwise specified herein, "substituted" to "substituted" means that one or more hydrogen atoms in the functional group of the present invention is a halogen atom (F, Br, Cl or I), a hydroxyl group, a nitro group, a cyano group, an amino group ( NH ₂ , NH(R ²⁰⁰ ) or N(R ²⁰¹ )(R ²⁰² ), wherein R ²⁰⁰ , R ²⁰¹ and R ²⁰² are the same or different from each other, and are each independently a C1 to C10 alkyl group), an amidino group, A hydrazine group, a hydrazone group, a carboxyl group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted alicyclic organic group, a substituted or unsubstituted aryl group, And means substituted with one or more substituents selected from the group consisting of a substituted or unsubstituted heterocyclic group.

In this specification, unless otherwise specified, "alkyl group" means a C1 to C20 alkyl group, specifically means a C1 to C15 alkyl group, and "cycloalkyl group" means a C3 to C20 cycloalkyl group, specifically C3 to C18 cycloalkyl group, "alkoxy group" means a C1 to C20 alkoxy group, specifically means a C1 to C18 alkoxy group, "aryl group" means a C6 to C20 aryl group, and specifically means a C6 to C20 alkoxy group. Means a C18 aryl group, "alkenyl group" means a C2 to C20 alkenyl group, specifically means a C2 to C18 alkenyl group, "alkylene group" means a C1 to C20 alkylene group, specifically C1 to C18 alkylene group, and "arylene group" means a C6 to C20 arylene group, specifically a C6 to C16 arylene group.

Unless otherwise defined herein, "combination" means mixing or copolymerization.

Hereinafter, an anti-aging composition according to an embodiment will be described.

The present inventors confirmed that the expression of the modified lamin A protein increased when fibroblasts were treated with ultraviolet light and the cell nuclear membrane structure was modified. It was further confirmed that the morphology of caused damage such as being crushed. Therefore, if it is possible to determine whether lamin A structural damage is reduced (lamin A structural damage recovery) after treatment with an effective substance to fibroblasts and UV stimulation, it is expected that aging caused by UV rays can be prevented or suppressed. As a result of anticipating and repeating research after study, the present invention was completed.

An anti-aging composition according to an embodiment includes a first material containing a phytoplacenta extract, a second material containing growth hormone, and a third material containing core-shell particles, wherein the core contains an active material, and the shell comprises the core. It consists of an inner shell surrounding the inner shell and an outer shell located on the outermost layer of the shell while surrounding the inner shell, and the inner shell is composed of zein, hordein, secalin, capirin ( kafirin), gliadin, oryzin, and at least one selected from the group consisting of avenin, the outer shell includes pullulan and pectin, and the second material is It is included in a concentration of 2.1% or more relative to the total concentration of the aging composition.

When the anti-aging composition according to one embodiment has the above configuration, transdermal absorption of the active substance can be promoted, and when used in the form of an external preparation for skin, a very excellent skin anti-aging effect can be expected. In particular, when the concentration of the second material is within the above range, the lamin A structure, which is a nuclear membrane protein modified by ultraviolet stimulation, can be significantly restored, and thus anti-aging functionality can be obtained.

Specifically, in the third material, components constituting the core and components constituting the shell, which may contain active substances, form a core-shell structure with each other, and furthermore, particles constituting the core-shell structure may form a network structure. have. For example, the pullulan included in the outer shell surrounds the core and the inner shell, and the pectin included in the outer shell is located in the outermost layer of the shell, forming an interconnection network between particles composed of the core and the inner shell Thus, a network structure can be achieved (see FIG. 1).

In addition, the network structure can serve as a carrier for promoting transdermal absorption of the active substance, so that the effect of promoting the percutaneous absorption of the active substance included in the core can be maximized.

For example, the efficacious material may be a hydrophobic material, including, for example, saponin, but is not necessarily limited thereto, and any efficacious material known to have a specific effect (even if it is not an anti-aging effect) is an efficacious material without particular limitation. can be used as

For example, the saponin may be camellia seed-derived saponin (camoreoside). The camellia seed-derived saponin is optimized for the anti-aging composition according to an embodiment compared to saponin derived from other substances, so that percutaneous absorption can be maximized.

For example, the camellia seed-derived saponin may be any one or a combination of two or more of the 15 compounds disclosed in FIG. 7 .

For example, the core may further include maltodextrin. That is, the core may include the saponin and maltodextrin, and in this case, the maltodextrin may be included in a greater amount than the saponin. For example, the saponin and maltodextrin may be included in a weight ratio of 1:99 to 20:80, for example, 5:95 to 15:85, for example 10:90. When the mixed weight ratio of saponin and maltodextrin in the core is within the above range, it may be advantageous to improve the anti-aging effect, in particular, the skin anti-aging effect induced by ultraviolet rays.

For example, the outer shell includes pullulan, which is a hydrophilic polysaccharide, and pectin. In this case, the pullulan may be included in a greater amount than the pectin. The pullulan may sufficiently surround the core and the inner shell only when the pullulan is included in an amount greater than that of the pectin. For example, the content (weight) of the pullulan may be 5 times or more, such as 6 times or more, such as 7 times or more, such as 8 times or more, such as 9 times or more, such as 10 times or more of the pectic content (weight). For example, when the pullulan is included in an amount equal to or less than that of the pectin, the pullulan does not sufficiently surround the core and the inner shell, so that the core-shell structure is not well formed, or the core and the inner shell The network structure may not be formed well because the mutual network between them is not well formed.

For example, the inner shell may include a bipolar plant protein, such as zein.

For example, the third material may further include hexanediol, ethylhexylglycerin, citric acid, water, or a combination thereof. In this case, the citric acid may be included in the smallest content among the constituents constituting the third material, and the water may be included in the highest content among constituents constituting the third material. If excluded, the hexanediol, for example, 1,2-hexanediol may be included in the largest amount among the components constituting the third material.

For example, the growth hormone contained in the second material may include a compound represented by Formula 1 below.

[Formula 1]

In Formula 1,

X is *-NH-*, *-O-*, *-S-* or *-CR ² R ³ (R ² and R ³ are each independently a hydrogen atom or a substituted or unsubstituted C1 to C10 alkyl group) ego,

R ¹ is a substituted or unsubstituted C1 to C20 alkyl group or carboxyl group.

For example, R ¹ may be a C1 to C20 alkyl group substituted with a carboxyl group.

For example, the second material may further include C1 to C20 alkylene glycol (eg, propylene glycol, butylene glycol, etc.), a disaccharide, water, or a combination thereof.

For example, the disaccharide may be sucrose, but is not necessarily limited thereto. In this case, the C1 to C20 alkylene glycol may be included in a larger content than the disaccharide, and the water may be included in the largest content among the components constituting the second material, except for the water, The C1 to C20 alkylene glycol, such as propylene glycol and/or butylene glycol, may be included in the largest amount among components constituting the second material. In addition, the growth hormone including the compound represented by Chemical Formula 1 may be included in the smallest content.

For example, the phytoplacenta extract contained in the first material may include a rye phytoplacenta extract.

For example, the first material may further include glycerin. At this time, the rye phytoplacenta extract may be included in a smaller content than the glycerin. For example, the rye phytoplacenta extract and glycerin may be included in a weight ratio of 1:99 to 10:90, such as 3:97 to 7:93, such as 5:95.

For example, the average particle size of the core-shell particles may be greater than 100 nm and less than 600 nm. The average particle size means the average of the largest diameters within the particle, and the average particle size means the average of the sizes of core-shell particles of at least 90% or more distributed in the composition. Specifically, the average of the particle sizes distributed in the composition is at least 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more Alternatively, it may mean the average value of the largest diameter in particles of 99% or more droplets. According to one embodiment, the hydrophobic effective material-containing core is coated with hydrophilic polysaccharides such as pullulan and pectin, and the core-shell particles are tightly interconnected with each other. As a result, the composition including the core-shell network structure can maintain a structure in which particles having an average particle size of more than 100 nm to 600 nm or less are evenly distributed can be stably maintained for a long time without precipitation, and as a delivery vehicle that effectively delivers active substances to the lower stratum corneum of the skin. can function Specifically, the average particle size of the core-shell particles may be 101 nm or more, 150 nm or more, 200 nm or more, 250 nm or more, 300 nm or more, 350 nm or more, 400 nm or more, 450 nm or more, 500 nm or more, or 550 nm or more. have. Specifically, the average particle size of the core-shell particles may be 600 nm or less, 550 nm or less, 500 nm or less, 450 nm or less, 400 nm or less, 350 nm or less, 300 nm or less, 250 nm or less, 200 nm or less, or 150 nm or less. However, it is not necessarily limited thereto.

For example, the content of the second material may be equal to or less than each of the first and second materials.

For example, the second material may be included in a concentration of 2.1% or more relative to the total concentration of the anti-aging composition. For example, the second material may be included at a concentration of 25 ppm or more, for example, 25 ppm to 100 ppm. When the concentration of the second material is within the above range, the lamin A structure, which is a nuclear membrane protein modified by UV stimulation, can be more significantly recovered.

For example, the ultraviolet light may be ultraviolet A (UVA), ultraviolet B (UVB), or ultraviolet C (UVC).

Another embodiment provides a composition for external application for skin comprising the anti-aging composition.

For example, when the anti-aging composition is applied to the skin, the dosage may be 1 mg/kg/day to 1 g/kg/day. For example, the dosage of the anti-aging composition may vary depending on the age, sex, weight, specific disease or pathological condition of the subject, the severity of the disease or pathological condition, the route of administration, etc., based on these factors. Dosage determination is within the level of the skilled artisan. For example, the dosage is 1 mg/kg/day or more, 2 mg/kg/day or more, 3 mg/kg/day or more, 4 mg/kg/day or more, 5 mg/kg/day or more, 10 mg /kg/day or more, 20 mg/kg/day or more, 30 mg/kg/day or more, 40 mg/kg/day or more, 50 mg/kg/day or more, 60 mg/kg/day or more, 70 mg/kg ≥ 80 mg/kg/day, ≥ 90 mg/kg/day, ≥ 100 mg/kg/day, ≥ 110 mg/kg/day, ≥ 120 mg/kg/day, 130 mg/kg/day 140 mg/kg/day or more, 150 mg/kg/day or more, 160 mg/kg/day or more, 170 mg/kg/day or more, 180 mg/kg/day or more, 190 mg/kg/day or more; 200 mg/kg/day or more, 250 mg/kg/day or more, 300 mg/kg/day or more, 350 mg/kg/day or more, 400 mg/kg/day or more, 450 mg/kg/day or more, or 500 mg Can be more than /kg/day. In addition, the dosage is, for example, 1 g / kg / day or less, 500 mg / kg / day or less, 450 mg / kg / day or less, 400 mg / kg / day or less, 350 mg / kg / day or less, 300 mg/kg/day or less, 250 mg/kg/day or less, 200 mg/kg/day or less, 190 mg/kg/day or less, 180 mg/kg/day or less, 170 mg/kg/day or less, 160 mg /kg/day or less, 150 mg/kg/day or less, 140 mg/kg/day or less, 130 mg/kg/day or less, 120 mg/kg/day or less, 110 mg/kg/day or less, or 100 mg/kg / day or less, but the dosage is not intended to limit the scope of the present specification in any way.

For example, the composition for external application for skin may be a cosmetic composition.

For example, the cosmetic composition may be formulated by containing a cosmetically or dermatologically acceptable medium or base. These are all formulations suitable for topical application, e.g. solutions, gels, solids, pasty anhydrous products, emulsions obtained by dispersing an oil phase in an aqueous phase, suspensions, microemulsions, microcapsules, microgranules or ionic (liposomes) nonionic It may be provided in the form of vesicular dispersions and films, or in the form of creams, toners, lotions, powders, ointments, sprays or conceal sticks. It can also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant. These compositions can be prepared according to conventional methods in the art.

For example, the cosmetic composition may also contain other ingredients that can give a synergistic effect to the main effect within a range that does not impair the main effect in addition to the active ingredient, and other ingredients in addition to the active ingredient of the present invention Depending on the formulation or purpose of use of other cosmetic compositions, those skilled in the art can select and blend them without difficulty. In addition, the cosmetic composition may include other ingredients normally formulated in cosmetic compositions as needed in addition to the above ingredients. For example, moisturizers, emollients, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, bactericides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, fragrances, blood circulation promoters, cooling agents, antiperspirants, Purified water etc. are mentioned. Other ingredients that may be included in the cosmetic composition of the present invention are not limited thereto, and the blending amount of the ingredients is possible within a range that does not impair the purpose and effect of the present invention.

For example, the composition for external application for skin may be a pharmaceutical composition.

For example, the pharmaceutical composition may further contain pharmaceutical adjuvants such as preservatives, stabilizers, hydration or emulsification accelerators, salts and/or buffers for osmotic pressure control, and other therapeutically useful substances. Specifically, the pharmaceutical composition may be a parenteral administration agent, and the parenteral administration agent may be a formulation for rectal, topical, subcutaneous, or transdermal administration. For example, it may be a formulation such as an injection, drops, ointment, lotion, gel, cream, spray, suspension, emulsion, suppository, patch, etc., but is not limited thereto.

For example, the dosage of the pharmaceutical composition will vary depending on the age, sex, and weight of the subject to be treated, the specific disease or pathological condition to be treated, the severity of the disease or pathological condition, the route of administration, and the prescriber's judgment. Dosage determination based on these factors is within the skill of the art. For example, the dosage may be 1 mg/kg/day or more or 500 mg/kg/day or more, and may be 1 g/kg/day or less, 500 mg/kg/day or less, or 100 mg/kg/day or less, The dosage is not intended to limit the scope of the present specification in any way.

For example, the composition for external application for skin may be a composition for preventing cell nuclear membrane damage induced by ultraviolet irradiation or a composition for inhibiting the expression of a modified lamin A protein.

Hereinafter, the contents of the present invention will be described in more detail through Examples and Comparative Examples. These examples are only presented to understand the contents of the present invention, but the scope of the present invention is not limited to these examples and test examples, and modifications, substitutions, and insertions commonly known in the art can be performed. It may be, and it is also included in the scope of the present invention.

Preparation of anti-aging composition

An anti-aging composition according to Example 1 was prepared with the composition shown in Table 1 below. A and D in Table 1 below form a core-shell network structure in the anti-aging composition, and a specific manufacturing method is as follows.

(Powdered zein is weighed and added to an aqueous alcohol solution, stirred and dissolved, and then saponin derived from camellia seeds (Hyundai Bioland Co., Ltd.) is weighed into the solution together with maltodextrin as an active ingredient. Stirred and dispersed sufficiently to ensure hydrophobic interaction between the pectin and the active substance Then, measure and add pullulan dissolved in the water phase at room temperature of pH 7 or less, stir and dissolve, and then measure the pectin in the water phase and add it to the solution And the alcohol of the solution was evaporated with an evaporator to obtain a final core-shell network solution dissolved in the aqueous phase.)

(unit: ppm) Example 1 A 250 B 250 C 25 D 625

A: Camellia seed-derived saponin (10wt%) + maltodextrin (90wt%)

B: Rye Phytoplacenta Extract (5wt%) + Glycerin (95wt%)

C: water (54wt%) + butylene glycol (40wt%) + sucrose (5.99wt%) + a compound represented by Formula 1A (0.01wt%; Kisan Bio)

[Formula 1A]

D: water (97.7965wt%) + 1,2-hexanediol (2wt%) + ethylhexylglycerin (0.05wt%) + pullulan (0.025wt%) + zein (0.0125wt%) + pectin (0.0025wt%) + Citric acid (0.001wt%)

Cepotoxicity evaluation

After treating the anti-aging composition according to Example 1 to adult fibroblasts (HDFa; Human Dermal Fibroblasts adult; Gibco; #C-013-5C) for 18 hours, cytotoxicity was confirmed, and the results are shown in Table 2 below. shown in Specifically, the cell viability of adult fibroblasts (HDFa) without any treatment was set to 100%, and then, after treatment with the anti-aging composition according to Example 1, the cell viability of adult fibroblasts (HDFa) was confirmed. . Since adult fibroblasts (HDFa) are easy to observe changes in nuclear shape due to photoaging stimulation, evaluation experiments were conducted with them.

(unit: %) Example 1 Cell viability 90

From Table 2, it can be confirmed that the anti-aging composition according to Example 1 has no cytotoxicity.

Evaluation of recovery of lamin A structure damaged by UV stimulation

20mJ/cm ² UVB stimulation was given to untreated adult fibroblasts (HDFa) (control group) four times at 3-day intervals, followed by 30mJ/cm ² UVB stimulation (Comparative Example 1), and 30mJ/cm ² After giving UVB stimulation, the anti-aging composition according to Example 1 was divided and cultured for 2 days, respectively. Thereafter, lamin A was stained with green fluorescence (immunofluorescence staining method), and whether or not the lamin A structure was damaged was confirmed using a confocal microscope, and the results are shown in FIGS. 3 to 6 . In addition, the ratio of cells with damaged lamin A structures relative to the total number of cells present in the area measured by confocal microscopy was confirmed and shown in FIG. 2 as a graph.

Referring to FIG. 2, it can be seen that the proportion of cells with damaged lamin A structure increased in Comparative Example 1 (65.0%) compared to the control group (6.4%), from which it can be seen that the structure of lamin A is damaged by UVB. . On the other hand, when the anti-aging composition of Example 1 was treated, it was confirmed that the ratio of cells with damaged lamin A structure was significantly reduced to 39.5%. These results can also be confirmed from FIGS. 3 to 6 .

Although the preferred embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements of those skilled in the art using the basic concept of the present invention defined in the following claims are also present. It falls within the scope of the right of invention.

Claims (23)

A first substance containing a phytoplacenta extract;
a second substance containing growth hormone; and
a third material containing core-shell particles;
The core contains active substances including saponin and maltodextrin,
The shell is composed of an inner shell surrounding the core and an outer shell surrounding the inner shell and located on the outermost layer of the shell,
The inner shell is one selected from the group consisting of zein, hordein, secalin, kafirin, gliadin, oryzin, and avenin. including more than
The outer shell contains pullulan and pectin,
Anti-aging cosmetic composition. In paragraph 1,
Pullulan included in the outer shell surrounds the core and the inner shell,
The pectin contained in the outer shell is located in the outermost layer of the shell and forms an interconnection network between the particles composed of the core and the inner shell to form a network structure,
Anti-aging cosmetic composition. In paragraph 2,
The network structure is a delivery chain for promoting transdermal absorption of an efficacious substance,
Anti-aging cosmetic composition. delete delete In paragraph 1,
The maltodextrin is included in a higher content than the saponin,
Anti-aging cosmetic composition. In paragraph 1,
The pullulan is included in a greater content than the pectin,
Anti-aging cosmetic composition. In paragraph 1,
The third material further comprises hexanediol, ethylhexylglycerin, citric acid, or a combination thereof.
Anti-aging cosmetic composition. In paragraph 1,
The growth hormone comprises a compound represented by Formula 1 below, an anti-aging cosmetic composition:
[Formula 1]

In Formula 1,
X is *-NH-*, *-O-*, *-S-* or *-CR ² R ³ (R ² and R ³ are each independently a hydrogen atom or a substituted or unsubstituted C1 to C10 alkyl group) ego,
R ¹ is a substituted or unsubstituted C1 to C20 alkyl group or carboxyl group. In paragraph 9,
The second material further comprises a C1 to C20 alkylene glycol, a disaccharide, or a combination thereof.
Anti-aging cosmetic composition. In paragraph 10,
The C1 to C20 alkylene glycol is included in a greater content than the disaccharide,
Anti-aging cosmetic composition. In paragraph 10,
Indoleacetic acid in the second material is included in the smallest content,
Anti-aging cosmetic composition. In paragraph 1,
The phytoplacenta extract includes rye phytoplacenta extract,
Anti-aging cosmetic composition. In paragraph 13,
The first material further comprises glycerin,
Anti-aging cosmetic composition. In paragraph 14,
The rye phytoplacenta extract is contained in a lower content than the glycerin,
Anti-aging cosmetic composition. In paragraph 1,
The average particle size of the core-shell particles is greater than 100 nm and less than 600 nm,
Anti-aging cosmetic composition. In paragraph 1,
The second material is included in an amount equal to or less than the content of the first material,
Anti-aging cosmetic composition. In paragraph 1,
The second material is included in a concentration of 25 ppm or more,
Anti-aging cosmetic composition. Comprising the anti-aging cosmetic composition of any one of claims 1 to 3 and 6 to 18,
A composition for external application to the skin. delete delete In paragraph 19,
The composition for external application for skin is a composition for preventing cell nuclear membrane damage induced by ultraviolet irradiation,
A composition for external application to the skin. In paragraph 19,
The composition for external application for skin is a composition for inhibiting the expression of a modified lamin A protein,
A composition for external application to the skin.

Images